In BRCA1/2 or PALB2 carriers with stage 3 or 4 pancreatic cancer, the combination of cisplatin + gemtricitabine with veliparib (a PARP inhibitor), did NOT seem to provide additional benefit over cisplatin + gemtricitabine alone.
Through this phase 2 randomized control trial, response rates in both treatment arms were high with similar overall survival rates. The take-home point is that the cisplatin/gemcitabine regimen showed a tremendous response for these patients (and veliparib did not really provide additional benefit). Additional trials are ongoing to study these drugs further in pancreatic cancer patients.
Check out the full article at https://www.ncbi.nlm.nih.gov/pubmed/31976786